Aclaris Therapeutics Announced Phase 1b Proof-of-Concept Primary Analysis Results For ATI-052 In Atopic Dermatitis, Asthma, Demonstrating Rapid, Durable Skin, Itch Improvement, Improved Lung Function, Airway Inflammation

뉴스 본문을 불러오고 있어요.

Aclaris Therapeutics Announced Phase 1b Proof-of-Concept Primary Analysis Results For ATI-052 In Atopic Dermatitis, Asthma, Demonstrating Rapid, Durable Skin, Itch Improvement, Improved Lung Function, Airway Inflammation | 웨이프 WAPE

Aclaris Therapeutics Announced Phase 1b Proof-of-Concept Primary Analysis Results For ATI-052 In Atopic Dermatitis, Asthma, Demonstrating Rapid, Durable Skin, Itch Improvement, Improved Lung Function, Airway Inflammation

기사 요약

관련 종목

댓글 —